Literature DB >> 21055938

Stem cells to treat muscular dystrophies - where are we?

Jinhong Meng1, Francesco Muntoni, Jennifer E Morgan.   

Abstract

The muscular dystrophies are inherited disorders characterised by progressive muscle wasting and weakness. Stem cell therapy is considered to be one of the most promising strategies for treating muscular dystrophies. In this review, we first examine the evidence that a stem cell could be used to treat muscular dystrophies, and then discuss the criteria that an ideal stem cell should meet. We also highlight the importance of standard operation procedures to be followed for ensuring the consistent and reproducible efficacy of a particular stem cell. While at the moment the scientific community is looking for an ideal stem cell to treat muscular dystrophies, it is clear that in order for this field to benefit from therapeutic stem cell applications, additional careful investigations are required.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21055938     DOI: 10.1016/j.nmd.2010.10.004

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  23 in total

Review 1.  Pericytes at the intersection between tissue regeneration and pathology.

Authors:  Alexander Birbrair; Tan Zhang; Zhong-Min Wang; Maria Laura Messi; Akiva Mintz; Osvaldo Delbono
Journal:  Clin Sci (Lond)       Date:  2015-01       Impact factor: 6.124

Review 2.  Duchenne muscular dystrophy: current cell therapies.

Authors:  Dorota Sienkiewicz; Wojciech Kulak; Bożena Okurowska-Zawada; Grażyna Paszko-Patej; Katarzyna Kawnik
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

Review 3.  Emerging drugs for Duchenne muscular dystrophy.

Authors:  Vinod Malik; Louise R Rodino-Klapac; Jerry R Mendell
Journal:  Expert Opin Emerg Drugs       Date:  2012-06       Impact factor: 4.191

4.  Fast-degradable microbeads encapsulating human umbilical cord stem cells in alginate for muscle tissue engineering.

Authors:  Jun Liu; Hongzhi Zhou; Michael D Weir; Hockin H K Xu; Qianming Chen; Carroll Ann Trotman
Journal:  Tissue Eng Part A       Date:  2012-07-19       Impact factor: 3.845

5.  Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model.

Authors:  Elena Serena; Susi Zatti; Alice Zoso; Francesca Lo Verso; F Saverio Tedesco; Giulio Cossu; Nicola Elvassore
Journal:  Stem Cells Transl Med       Date:  2016-08-08       Impact factor: 6.940

6.  Phospho-tyrosine phosphatase inhibitor Bpv(Hopic) enhances C2C12 myoblast migration in vitro. Requirement of PI3K/AKT and MAPK/ERK pathways.

Authors:  Georgi A Dimchev; Nasser Al-Shanti; Claire E Stewart
Journal:  J Muscle Res Cell Motil       Date:  2013-04-04       Impact factor: 2.698

7.  Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy.

Authors:  Wendy K M Liew; Peter B Kang
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

8.  The Rag2⁻Il2rb⁻Dmd⁻ mouse: a novel dystrophic and immunodeficient model to assess innovating therapeutic strategies for muscular dystrophies.

Authors:  Denis Vallese; Elisa Negroni; Stéphanie Duguez; Arnaud Ferry; Capucine Trollet; Ahmed Aamiri; Christian A J Vosshenrich; Ernst-Martin Füchtbauer; James P Di Santo; Libero Vitiello; Gillian Butler-Browne; Vincent Mouly
Journal:  Mol Ther       Date:  2013-08-23       Impact factor: 11.454

9.  Cellular Transplantation Alters the Disease Progression in Becker's Muscular Dystrophy.

Authors:  Alok Sharma; Amruta Paranjape; Hemangi Sane; Khushboo Bhagawanani; Nandini Gokulchandran; Prerna Badhe
Journal:  Case Rep Transplant       Date:  2013-06-06

10.  UtroUp is a novel six zinc finger artificial transcription factor that recognises 18 base pairs of the utrophin promoter and efficiently drives utrophin upregulation.

Authors:  Annalisa Onori; Cinzia Pisani; Georgios Strimpakos; Lucia Monaco; Elisabetta Mattei; Claudio Passananti; Nicoletta Corbi
Journal:  BMC Mol Biol       Date:  2013-01-30       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.